Glenmark receives USFDA approval for Chlorpromazine Hydrochloride Tablets

Image
Capital Market
Last Updated : Mar 24 2021 | 9:31 AM IST
Glenmark Pharmaceuticals has received approval by the United States Food & Drug Administration (USFDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, the generic version of Thorazine1 Tablets, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, of GlaxoSmithKline.

Glenmark has been granted a competitive generic therapy (CGT) designation for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing.

According to IQVIATM sales data for the 12 month period ending January 2021, the Thorazine1 Tablets, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg market achieved annual sales of approximately $108.6 million.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Mar 24 2021 | 9:16 AM IST

Next Story